Open AccessLenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports
Author(s) -
Satoshi Komiyama,
Kazushi Numata,
Satoshi Moriya,
Hiroyuki Fukuda,
Makoto Chuma,
Shin Maeda
Publication year - 2020
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v8.i12.2574
Subject(s) - lenvatinib , medicine , sorafenib , hepatocellular carcinoma , liver function , gastroenterology , oncology , radiology
In a phase III trial of lenvatinib as first-line treatment for advanced unresectable hepatocellular carcinoma (uHCC), the drug proved non-inferior to sorafenib in terms of the overall survival, but offered better progression-free survival. However, the effects of lenvatinib in uHCC patients with a tumor thrombus in the main portal vein and/or a high tumor burden (tumor occupancy more than 50% of the total liver volume), remain unclear, because these were set as exclusion criteria in the aforementioned trial.